keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg seroconversion

keyword
https://www.readbyqxmd.com/read/29158122/biomarkers-distinguish-hbeag-seroconverted-from-non-converted-individuals-in-chronic-hepatitis-b-patients-treated-with-a-therapeutic-vaccine
#1
Xian Zhou, Shuang Geng, Shijie Zhang, Weidong Zhao, Gan Zhao, Yumei Wen, Xuanyi Wang, Bin Wang
Cytokine assays of host immune responses to vaccination can indicate vaccine efficacy. Here we tested the hypothesis that assays of the cytokine status of infected individuals prior to therapeutic vaccination might provide a guide to vaccine therapeutic efficacy. If so, cytokine analysis might be used to select appropriate patients for therapeutic vaccination. Data were obtained from a panel of 14 cytokine/chemokine assays that were done during a phase III clinical trial of HBsAg-HBIG therapeutic vaccine (YIC) treatment of chronic hepatitis B (CHB) patients...
November 17, 2017: Cytokine
https://www.readbyqxmd.com/read/29131246/study-on-the-distribution-of-cd8-memory-t-cell-subsets-and-ifn-%C3%AE-level-during-the-spontaneous-clearance-of-hepatitis-b-virus-in-patients-with-chronic-hepatitis-b-virus-infection
#2
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29091317/the-change-of-antibody-levels-in-children-changes-and-analysis-of-anti-hbs-titers-after-primary-immunization-in-1-16-year-old-chinese-children-a-hospital-based-study
#3
Xiaomei Yue, Congcong Ge, Shurui Zhuge, Hao He, Hui Yang, Hongmei Xu, Ailong Huang, Yao Zhao
Immunization with the hepatitis B vaccine is the most effective measure to prevent Hepatitis B Virus (HBV) infection. The aim of this study was to investigate the change in antibody levels induced by administration of the hepatitis B vaccine in children aged 1-16 year-old in a large sample sized investigation. HBV markers were determined in 93,326 1-16 year-old hospitalized children who completed primary immunization as infants from southwest China, Chongqing. Analyses were performed on anti-HBs titer changes with increasing age, and the revaccination effect was evaluated in children aged 7-14...
November 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082652/long-term-outcome-of-telbivudine-versus-entecavir-in-treating-higher-viral-load-chronic-hepatitis-b-patients-without-cirrhosis
#4
H-Y Pan, H-Y Pan, W-Y Song, W Zheng, Y-X Tong, D-H Yang, Y-N Dai, M-J Chen, M-S Wang, Y-C Huang, J-J Zhang, H-J Huang
Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load [HVL], HBV DNA ≥1 × 10(7) copies/mL) require antiviral therapy, but data for evaluating the long-term outcome of this therapy with antiviral agents remain limited. We comparatively evaluated the efficacy and the safety of nucleoside analogues in 179 noncirrhotic CHB patients with HVL over 5 years. The HBeAg-positive (n = 104) or HBeAg-negative (n = 75) patients were treated consecutively with telbivudine (LdT, n = 88) or entecavir (ETV, n = 91) and evaluated for viral response, drug resistance and safety...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#5
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082646/safety-and-efficacy-of-telbivudine-for-chronic-hepatitis-b-during-the-entire-pregnancy-long-term-follow-up
#6
J Shang, Q Wen, C C Wang, K Liu, L Bai, H Tang
The management of hepatitis B virus (HBV) infection in pregnancy is a unique issue. Telbivudine (LdT) is recommended to block HBV mother-to-child transmission (MTCT) in the third trimester. However, the safety of LdT treatment during the entire pregnancy for the long-term growth of infants is unclear. The aim of this study was to evaluate the efficacy and long-term safety of LdT for the entire pregnancy period. This retrospective cohort study included 40 pregnant women and 43 children from 2011 to 2017. The antiviral effects and maternal abnormalities were evaluated...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29072673/seven-year-treatment-outcome-of-entecavir-in-a-real-world-cohort-effects-on-clinical-parameters-hbsag-and-hbcrag-levels
#7
Yuk-Fai Lam, Wai-Kay Seto, Danny Wong, Ka-Shing Cheung, James Fung, Lung-Yi Mak, John Yuen, Chun-Kong Chong, Ching-Lung Lai, Man-Fung Yuen
OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients. METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic, virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined...
October 26, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/29056008/-clinical-effect-and-safety-of-pegylated-interferon-%C3%AE-2b-injection-y-shape-40-kd-in-treatment-of-hbeag-positive-chronic-hepatitis-b-patients
#8
F Q Hou, Y L Yin, L Y Zeng, J Shang, G Z Gong, C Pan, M X Zhang, C B Yin, Q Xie, Y Z Peng, S J Chen, Q Mao, Y P Chen, Q G Mao, D Z Zhang, T Han, M R Wang, W Zhao, J J Liu, Y Han, L F Zhao, G H Luo, J M Zhang, J Peng, D M Tan, Z W Li, H Tang, H Wang, Y X Zhang, J Li, L L Zhang, L Chen, J D Jia, C W Chen, Z Zhen, B S Li, J Q Niu, Q H Meng, H Yuan, Y T Sun, S C Li, J F Sheng, J Cheng, L Sun, G Q Wang
Objective: To investigate the clinical effect and safety of long-acting pegylated interferon-α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 μg/week) in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients, with standard-dose Peg-IFN-α-2a as positive control. Methods: This study was a multicenter, randomized, open-label, and positive-controlled phase III clinical trial. Eligible HBeAg-positive CHB patients were screened out and randomized to Peg-IFN-α-2b (Y shape, 40 kD) trial group and Peg-IFN-α-2a control group at a ratio of 2:1...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29056007/-clinical-effect-of-156-week-telbivudine-sequential-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-pegylated-interferon-%C3%AE-2a-therapy
#9
X D Luo, X P Chen, X F Chen
Objective: To investigate the clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a (Peg-IFN-α-2a) therapy. Methods: A total of 35 HBeAg-positive CHB patients with HBV DNA < 500 IU/ml who were treated with Peg-IFN-α-2a for 48 weeks and did not experience seroconversion of HBeAg were given telbivudine sequential therapy for 156 weeks. HBeAg clearance rate, HBeAg seroconversion rate, HBV DNA clearance rate, safety, and drug resistance rate were analyzed...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29055925/clinical-analysis-of-polyethylene-glycol-interferon-%C3%AE-treatment-in-155-hepatitis-b-e-antigen-hbeag-positive-chronic-hepatitis-b-chb-patients
#10
Xin Luo, Ji-Xian Yu, Lei Xie, Wen-Jun Ma, Li-Hong Wang
PURPOSE: This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and 48th week after withdrawal, in order to provide guidance on the antiviral treatment of HBeAg-positive CHB patients. MATERIAL AND METHODS: Antiviral treatment was performed on 155 HBeAg-positive CHB patients. Among these patients, 66 patients received PEG-interferon α-2a treatment and 89 patients received PEG-interferon α-2b treatment; and these treatments were administered by subcutaneous injection, once per week, which lasted for 48 weeks...
October 16, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29042662/switching-to-pegifn%C3%AE-2b-leads-to-hbsag-loss-in-patients-with-low-hbsag-levels-and-hbv-dna-suppressed-by-nas
#11
Jing Huang, Ka Zhang, Wenli Chen, Jinyao Liao, Xiaodan Luo, Ren Chen
Patients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFNα in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg < 2,000 IU/ml and HBV DNA < 20 IU/ml were randomized to receive PegIFNα-2b or continuing NA therapy for 60 weeks. At the end of treatment (EOT) and end of follow-up (EOF), only patients who switched to PegIFNα-2b achieved HBsAg loss (32...
October 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29035003/hepatitis-b-core-related-antigen-hbcrag-an-emerging-marker-for-chronic-hepatitis-b-virus-infection
#12
REVIEW
L-Y Mak, D K-H Wong, K-S Cheung, W-K Seto, C-L Lai, M-F Yuen
BACKGROUND: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non-invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core-related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB...
October 16, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29023803/hbeag-levels-at-week-24-predict-response-to-8%C3%A2-years-of-tenofovir-in-hbeag-positive-chronic-hepatitis-b-patients
#13
D Wong, M Littlejohn, L Yuen, K Jackson, H Mason, J Bayliss, G Rosenberg, A Gaggar, K Kitrinos, M Subramanian, P Marcellin, M Buti, H L A Janssen, E Gane, S Locarnini, A Thompson, P A Revill
BACKGROUND: Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful. AIM: To evaluate the utility of measuring HBeAg levels for predicting HBeAg seroconversion and HBsAg loss under long-term tenofovir (TDF) therapy. METHODS: A total of 266 patients were enrolled into a phase III study of TDF vs adefovir (ADV) for 48 weeks in HBeAg-positive patients, followed by open-label TDF up to 384 weeks...
October 11, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28988797/altered-expression-of-interferon-stimulated-genes-is-strongly-associated-with-therapeutic-outcomes-in-hepatitis-b-virus-infection
#14
Meifang Han, Yong Li, Wenyu Wu, Yuanya Zhang, Weiming Yan, Xiaoping Luo, Qin Ning
Our previous OSST study shows that switching to pegylated interferon (Peg-IFN)-α2a results in higher rates of response hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss at the end of treatment, compared with nucleot(s)ide analogues (NAs) monotherapy in long term NA-treated chronic hepatitis B (CHB) patients. In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study...
October 6, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28984383/evaluation-of-the-highly-sensitive-chemiluminescent-enzyme-immunoassay-lumipulse-hbsag-hq-for-hepatitis-b-virus-screening
#15
Matsuo Deguchi, Masanori Kagita, Nori Yoshioka, Hiroko Tsukamoto, Miyuki Takao, Kazuko Tahara, Ikuhiro Maeda, Yoh Hidaka, Satoshi Yamauchi, Atsushi Kaneko, Hideo Miyakoshi, Mitsuo Isomura
BACKGROUND: Ongoing efforts in the development of HBsAg detection kits are focused on improving sensitivity and specificity. The purpose of this study was to evaluate an improved, highly sensitive quantitative assay, "Lumipulse HBsAg-HQ", a chemiluminescent enzyme immunoassay designed for a fully automated instrument, the "Lumipulse G1200". METHODS: Serum samples for reproducibility, dilution, correlation, sensitivity, and specificity studies were obtained from patients at the Osaka University Hospital...
October 6, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28977667/successful-use-of-entecavir-in-hepatitis-b-associated-membranous-nephropathy
#16
Vidushi Mahajan, Sanjay D'Cruz, Ritambara Nada, Atul Sachdev
We report the case of a 7-year-old unimmunized boy who presented with generalized anasarca for the first time, along with nephrotic-range proteinuria, hypoalbuminemia, microscopic hematuria and hypertension. Special investigations revealed ELISA test to be positive for hepatitis B surface antigen (HBsAg) and hepatitis B envelope antigen (HBeAg); hepatitis B viral DNA load (HBV DNA) level (real-time polymerase chain reaction) was 54 360 903 IU/ml. For hepatitis B virus (HBV)-related glomerulopathy, he was started on enalapril and lasilactone, and percutaneous renal biopsy was performed, which revealed membranous nephropathy (MN)...
July 27, 2017: Journal of Tropical Pediatrics
https://www.readbyqxmd.com/read/28936408/emerging-trends-in-epidemiology-of-hepatitis-b-virus-infection
#17
REVIEW
Cristina Stasi, Caterina Silvestri, Fabio Voller
Although a vaccine against hepatitis B virus (HBV) has been available since 1982, the prevalence of adults with chronic HBV infection in sub-Saharan Africa and East Asia is still estimated at 5-10%. A high rate of chronic infections is also found in the Amazon and the southern parts of eastern and central Europe. In the Middle East and the Indian subcontinent, the prevalence is 2-5%. Less than 1% of the population of Western Europe and North America is chronically infected. Given the high prevalence of infections (such as hepatitis) among inmates, prison is considered a reservoir for facilitating such infections...
September 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28934424/the-impact-of-hepatitis-b-vaccine-failure-on-long-term-natural-course-of-chronic-hepatitis-b-virus-infection-in-hepatitis-b-e-antigen-seropositive-children
#18
Chi-San Tai, Jia-Feng Wu, Huey-Ling Chen, Yen-Hsuan Ni, Hong-Yuan Hsu, Mei-Hwei Chang
Background: Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in children after universal hepatitis B immunization. This study aimed to investigate the natural course of chronic HBV infection in children with vaccine failure and compare it with that of nonvaccinated children. Methods: Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, who were followed for at least 1 year without antiviral therapy, were enrolled...
September 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28933704/the-association-between-serum-cytokine-and-chemokine-levels-and-antiviral-response-by-entecavir-treatment-in-chronic-hepatitis-b-patients
#19
Mio Kurihara, Masataka Tsuge, Eisuke Murakami, Nami Mori, Waka Ohishi, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yizhou Zhang, Grace Naswa Makokha, C Nelson Hayes, Kazuaki Chayama
BACKGROUND: Although Nucleos(t)ide analogue therapy is thought to suppress chronic hepatitis B(CHB) via regulation of inflammatory cytokines/chemokines, the mechanism is still unclear. In this study, serum cytokine/chemokine levels were measured in CHB patients treated with entecavir, and the association with antiviral response was analyzed. METHODS: Seventy-eight Japanese patients with CHB were enrolled, and serum cytokine/chemokine levels were measured at baseline and at 12, 24, and 48 weeks of entecavir treatment using the MULTIPLEX kit...
September 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28923315/development-of-a-digital-droplet-pcr-assay-to-measure-hbv-dna-in-patients-receiving-long-term-tdf-treatment
#20
Yang Liu, Andrea L Cathcart, William E Delaney, Kathryn M Kitrinos
The COBAS TaqMan assay has a lower limit of quantification (LLOQ) of 169 HBV copies/mL and a lower limit of detection (LLOD) of 58 copies/mL. HBV DNA below the TaqMan LLOQ is classified as target not detected (TND) (<58 copies/mL) or target detected (TD) (between 58 and 169 copies/mL). Here we have developed a more sensitive digital droplet PCR (ddPCR) assay to evaluate the impact of long-term tenofovir disoproxil fumarate (TDF) treatment in patients that did or did not achieve HBsAg seroconversion. A ddPCR assay was developed to detect HBV DNA to 8 copies/mL...
September 18, 2017: Journal of Virological Methods
keyword
keyword
31626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"